Welcome to our dedicated page for Angiodynamics SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
Divisadero Street Capital and related entities report ownership of material stakes in AngioDynamics common stock. The filing shows Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 3,395,430 shares, representing 8.4% of the class, while Divisadero Street Partners, L.P. and its GP report 3,054,469 shares (approximately 7.5%). The reported positions are held with shared voting and dispositive power only; no reporting person asserts sole voting or sole dispositive power.
The filing states that all reported securities are directly owned by advisory clients of Divisadero Street Capital Management, LP and that each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. The filing includes a joint filing agreement and a control-person identification exhibit.
AngioDynamics, Inc. (NASDAQ: ANGO) filed a Form 8-K on July 15, 2025 to furnish—rather than file—materials related to its fiscal fourth-quarter and full-year results ended May 31, 2025.
- Item 2.02: The company issued a press release (Exhibit 99.1) announcing its Q4 and FY 2025 financial performance.
- Item 7.01: Investor presentation slides (Exhibit 99.2) discussing the same period were also provided.
- Both exhibits are expressly excluded from Exchange Act Section 18 liability and will not be incorporated into future Securities Act or Exchange Act filings unless specifically referenced.
- No quantitative results, guidance, or commentary appear in the 8-K text itself; investors must review the furnished exhibits for details.
The filing contains standard forward-looking-statement disclaimers and lists common risk factors that could cause actual results to differ.